Join the club for FREE to access the whole archive and other member benefits.

GENFIT

Company discovering and developing innovative therapeutic and diagnostic solutions targeting liver diseases.

GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments.

GENFIT is a leader in the field of nuclear receptor-based drug discovery with a rich history and strong scientific heritage spanning almost two decades. Its most advanced drug candidate, elafibranor, is currently evaluated in pivotal Phase 3 clinical trial (“RESOLVE-IT”) as a potential treatment for nonalcoholic steatohepatitis, or NASH. NASH is considered by regulatory authorities as a medical emergency because of its potentially severe consequences, although often asymptomatic until late stages, and because its prevalence is on the rise. Elafibranor has also obtained positive preliminary results in a Phase 2 clinical trial in primary biliary cholangitis (PBC), a severe chronic liver disease.

Visit website: https://www.genfit.com/

 genfit

 genfit_pharma

 UCjaCLkheErNvFMX9Y_A78lw

Details last updated 27-Feb-2021

GENFIT News

10 Hot European Biotechs to watch in 2016

Labiotech - 12-Jan-2016

Including immuno-oncology treatments, antibody delivery, Tau-aggregation inhibitors and mRNA ther...

Read more...
Topics mentioned on this page:
Laboratory Automation